First-Line Dacomitinib versus Gefitinib in Advanced Non-Small-Cell Lung Cancer with EGFR Mutation Subgroups

被引：0

作者：

Wu, Y. ^{[1
,2
]}

Cheng, Y. ^{[3
]}

Zhou, X. ^{[4
]}

Lee, K. H. ^{[5
]}

Nakagawa, K. ^{[6
]}

Niho, S. ^{[7
]}

Tsuji, F. ^{[8
]}

Rosell, R. ^{[9
]}

Corral, J. ^{[10
]}

Migliorino, M. R. ^{[11
]}

Pluzanski, A. ^{[12
]}

Linke, R. ^{[13
]}

Sbar, E. ^{[14
]}

Wang, T. ^{[15
]}

Zhang, H. ^{[16
]}

Mok, T. ^{[17
]}

机构：

[1] Guangdong Gen Hosp, Guangzhou, Guangdong, Peoples R China

[2] Guangdong Acad Med Sci, Guangzhou, Guangdong, Peoples R China

[3] Jilin Prov Canc Hosp, Changchun, Jilin, Peoples R China

[4] Third Mil Med Univ, Affiliated Hosp 1, Chongqing, Peoples R China

[5] Chungbuk Natl Univ Hosp, Chungcheongbuk Do, South Korea

[6] Kindai Univ Hosp, Osaka, Japan

[7] Natl Canc Ctr Hosp East, Kashiwa, Chiba, Japan

[8] Sfj Pharma Japan KK, Osaka, Japan

[9] Germans Trias I Pujol Hlth Sci Inst, Catalan Inst Oncol, Barcelona, Spain

[10] Hosp Univ Virgen Del Rocio, Seville, Spain

[11] San Camillo Forlanini Hosp, Pulm Oncol Unit, Rome, Italy

[12] Maria Sklodowska Curie Mem Canc Ctr & Inst Oncol, Warsaw, Poland

[13] Sfj Pharmaceut Grp, Pleasanton, CA USA

[14] Pfizer Oncol, Collegeville, PA USA

[15] Pfizer Oncol, Groton, CT USA

[16] Pfizer Oncol, Shanghai, Peoples R China

[17] Chinese Univ Hong Kong, Hong Kong, Peoples R China

来源：

JOURNAL OF THORACIC ONCOLOGY | 2017年 / 12卷 / 11期

关键词：

EGFR mutations; Dacomitinib; advanced non-small-cell lung cancer;

D O I：

10.1016/j.jtho.2017.09.347

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

OA 05.01

引用

页码：S1754 / S1754

页数：1

共 50 条

[11] Real-world data of dacomitinib as first-line treatment for patients with EGFR-mutant non-small-cell lung cancer [J].

Shin, Ji Eun ;

Jung, Hyun Ae ;

Park, Sehhoon ;

Sun, Jong-Mu ;

Lee, Se-Hoon ;

Ahn, Jin Seok ;

Ahn, Myung-Ju ;

Shim, Byoung Yong .

SCIENTIFIC REPORTS, 2025, 15 (01)

[12] Dacomitinib in the Management of Advanced Non-Small-Cell Lung Cancer [J].

Lau, Sally C. M. ;

Batra, Ullas ;

Mok, Tony S. K. ;

Loong, Herbert H. .

DRUGS, 2019, 79 (08) :823-831

[13] Management of common adverse events related to first-line dacomitinib use in EGFR mutation-positive non-small-cell lung cancer: a pooled safety analysis [J].

Zhou, Qing ;

Wu, Yi-Long ;

Corral, Jesus ;

Nakagawa, Kazuhiko ;

Garon, Edward B. ;

Sbar, Eric I. ;

Wang, Tao ;

Sandin, Rickard ;

Noonan, Kay ;

Gernhardt, Diana ;

Mok, Tony S. .

FUTURE ONCOLOGY, 2019, 15 (13) :1481-1491

[14] Redefining Treatment Paradigms in First-line Advanced Non-Small-Cell Lung Cancer [J].

Heigener, David F. ;

Kerr, Keith M. ;

Laing, Gavin M. ;

Mok, Tony S. K. ;

Moiseyenko, Fedor V. ;

Reck, Martin .

CLINICAL CANCER RESEARCH, 2019, 25 (16) :4881-4887

[15] Safety and efficacy of first-line dacomitinib in Japanese patients with advanced non-small cell lung cancer [J].

Nishio, Makoto ;

Kato, Terufumi ;

Niho, Seiji ;

Yamamoto, Noboru ;

Takahashi, Toshiaki ;

Nogami, Naoyuki ;

Kaneda, Hiroyasu ;

Fujita, Yuka ;

Wilner, Keith ;

Yoshida, Mizuki ;

Isozaki, Mitsuhiro ;

Wada, Shinsuke ;

Tsuji, Fumito ;

Nakagawa, Kazuhiko .

CANCER SCIENCE, 2020, 111 (05) :1724-1738

[16] Dacomitinib Versus Gefitinib for First-Line Treatment of Advanced EGFR plus NSCLC in Japanese Patients (ARCHER 1050) [J].

Nakagawa, K. ;

Ohyanagi, F. ;

Kato, T. ;

Takahashi, T. ;

Kaneda, H. ;

Nogami, N. ;

Niho, S. ;

Yamamoto, N. ;

Fujita, Y. ;

Zhang, H. ;

Sbar, E. ;

Wang, H. ;

Linke, R. ;

Tsuji, F. ;

Mok, T. .

JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) :S2229-S2230

[17] Dacomitinib as a retreatment for advanced non-small cell lung cancer patient with an uncommon EGFR mutation [J].

Morita, Ayako ;

Hosokawa, Shinobu ;

Yamada, Kotaro ;

Umeno, Takahiro ;

Kano, Hirohisa ;

Kayatani, Hiroe ;

Shiojiri, Masaaki ;

Sakugawa, Makoto ;

Bessho, Akihiro .

THORACIC CANCER, 2021, 12 (08) :1248-1251

[18] Cost-effectiveness analysis of the first-line EGFR-TKIs in patients with advanced EGFR-mutated non-small-cell lung cancer [J].

Aguilar-Serra, J. ;

Gimeno-Ballester, V ;

Pastor-Clerigues, A. ;

Milara, J. ;

Trigo-Vicente, C. ;

Cortijo, J. .

EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2022, 22 (04) :637-646

[19] Efficacy and safety of icotinib as first-line therapy in patients with advanced non-small-cell lung cancer [J].

Shen, Yan-Wei ;

Zhang, Xiao-Man ;

Li, Shu-Ting ;

Lv, Meng ;

Yang, Jiao ;

Wang, Fan ;

Chen, Zhe-Ling ;

Wang, Bi-Yuan ;

Li, Pan ;

Chen, Ling ;

Yang, Jin .

ONCOTARGETS AND THERAPY, 2016, 9 :929-935

[20] Real-world analysis of the effect of gefitinib as a first-line therapy in patients with advanced non-small cell lung cancer with EGFR mutations [J].

Pham Van Luan ;

Nguyen Dinh Tien ;

Nguyen Minh Hai ;

Nguyen Dao Tien ;

Thi Thi Duyen .

THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2021, 13

← 1 2 3 4 5 →